Besides, marmesin inhibits pRb phosphorylation in human umbilical vein endothelial cells (HUVECs) and in non-small cell lung cancer (NSCLC) cell lines (A549 and H1299) by suppressing the expression of Cdk4 and cyclin D; hence, the cell cycle is halted [51,52]. Here, CDK4 is linked to non-small cell lung carcinoma.